BNGO Quote, Financials, Valuation and Earnings

Azenta has a net margin of -728.57% compared to Bionano Genomics's net margin of -9.04%. Bionano Genomics's return on equity of -158.95% beat Azenta's return on equity of -7.97%.

Bionano Genomics has a consensus price target of --, signalling upside risk potential of 1629.1%. On the other hand Azenta has an analysts' consensus of $58.67 which suggests that it could grow by 58.7%. Given that Bionano Genomics has higher upside potential than Azenta, analysts believe Bionano Genomics is more attractive than Azenta.

Bionano Genomics has a beta of 2.247, which suggesting that the stock is 124.652% more volatile than S&P 500. In comparison Azenta has a beta of 1.521, suggesting its more volatile than the S&P 500 by 52.14%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.1M, which are smaller than Azenta quarterly revenues of $147.5M. Bionano Genomics's net income of -$44.2M is lower than Azenta's net income of -$13.3M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.08x versus 2.86x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -728.57% compared to Bionano Genomics's net margin of 1.4%. Bionano Genomics's return on equity of -158.95% beat Bruker's return on equity of 6.78%.

Bionano Genomics has a consensus price target of --, signalling upside risk potential of 1629.1%. On the other hand Bruker has an analysts' consensus of $68.42 which suggests that it could grow by 48.86%. Given that Bionano Genomics has higher upside potential than Bruker, analysts believe Bionano Genomics is more attractive than Bruker.

Bionano Genomics has a beta of 2.247, which suggesting that the stock is 124.652% more volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.406%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.44% to investors and pays a quarterly dividend of $0.05 per share. Bionano Genomics pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bionano Genomics quarterly revenues are $6.1M, which are smaller than Bruker quarterly revenues of $979.6M. Bionano Genomics's net income of -$44.2M is lower than Bruker's net income of $13.7M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Bruker's PE ratio is 60.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.08x versus 2.04x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -728.57% compared to Bionano Genomics's net margin of 0.07%. Bionano Genomics's return on equity of -158.95% beat Harvard Bioscience's return on equity of -18.36%.

Bionano Genomics has a consensus price target of --, signalling upside risk potential of 1629.1%. On the other hand Harvard Bioscience has an analysts' consensus of $4.25 which suggests that it could grow by 555.97%. Given that Bionano Genomics has higher upside potential than Harvard Bioscience, analysts believe Bionano Genomics is more attractive than Harvard Bioscience.

Bionano Genomics has a beta of 2.247, which suggesting that the stock is 124.652% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.371%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.1M, which are smaller than Harvard Bioscience quarterly revenues of $24.6M. Bionano Genomics's net income of -$44.2M is lower than Harvard Bioscience's net income of $18K. Notably, Bionano Genomics's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.08x versus 0.30x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Kestra Medical Technologies has a net margin of -728.57% compared to Bionano Genomics's net margin of --. Bionano Genomics's return on equity of -158.95% beat Kestra Medical Technologies's return on equity of --.

Bionano Genomics has a consensus price target of --, signalling upside risk potential of 1629.1%. On the other hand Kestra Medical Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Bionano Genomics has higher upside potential than Kestra Medical Technologies, analysts believe Bionano Genomics is more attractive than Kestra Medical Technologies.

Bionano Genomics has a beta of 2.247, which suggesting that the stock is 124.652% more volatile than S&P 500. In comparison Kestra Medical Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Kestra Medical Technologies pays out -1.99% of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.1M, which are larger than Kestra Medical Technologies quarterly revenues of --. Bionano Genomics's net income of -$44.2M is higher than Kestra Medical Technologies's net income of --. Notably, Bionano Genomics's price-to-earnings ratio is -- while Kestra Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.08x versus 21.49x for Kestra Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.